OTCM
ONWRF
Market cap137mUSD
Jun 09, Last price
4.55USD
Name
ONWARD Medical NV
Chart & Performance
P/E
—
P/S
1,508.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.47%
Rev. gr., 5y
-32.61%
Revenues
77k
-85.53%
Net income
-36m
L-1.26%
CFO
-32m
L-1.57%
Profile
Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 77 -85.53% | 532 -75.23% | 2,148 53.54% | |||||
Cost of revenue | 13,362 | 43,461 | 37,848 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (13,285) | (42,929) | (35,700) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (40) | 107 | (766) | |||||
Tax Rate | ||||||||
NOPAT | (13,245) | (43,036) | (34,934) | |||||
Net income | (35,725) -1.26% | (36,181) 10.40% | (32,772) -4.49% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 64,259 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 1,034 | 568 | 427 | |||||
Long-term debt | 14,490 | 17,925 | 15,671 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 3,999 | 2,081 | 1,121 | |||||
Net debt | (44,519) | (11,275) | (57,916) | |||||
| Cash flow | ||||||||
Cash from operating activities | (31,763) | (32,270) | (26,685) | |||||
CAPEX | (150) | (422) | (417) | |||||
Cash from investing activities | (150) | 19,578 | (20,417) | |||||
Cash from financing activities | 62,560 | 813 | (557) | |||||
FCF | (12,678) | (43,032) | (34,650) | |||||
| Balance | ||||||||
Cash | 60,043 | 29,768 | 61,760 | |||||
Long term investments | 12,254 | |||||||
Excess cash | 60,039 | 29,741 | 73,907 | |||||
Stockholders' equity | (169,720) | (137,318) | (102,618) | |||||
Invested Capital | 237,297 | 174,204 | 170,062 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 44,629 | 30,184 | 30,184 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (12,387) | (42,203) | (34,965) | |||||
EV/EBITDA | ||||||||
Interest | 1,999 | 600 | 1,515 | |||||
Interest/NOPBT | ||||||||